Glucose monitoring device developer Movano sets terms for $36 million IPO

Movano, which is developing a wearable device that measures glucose, blood pressure, and heart rate, announced terms for its IPO on Wednesday.

The Pleasanton, CA-based company plans to raise $36 million by offering 7.2 million shares at $5. At the proposed price, Movano would command a fully diluted market value of $164 million.

Movano is developing a proprietary platform that uses radio frequency (RF) technology, which it believes will enable the creation of low-cost and scalable sensors that are small enough to fit into a wearable device. The platform is the foundation for its first product in development, a non-invasive and cuffless wearable intended to combine the functionality of a continuous glucose monitor and a cuffless RF-based blood pressure monitor. The company currently plans to conduct pivotal trials for FDA 510(k) clearance in the 2H21. Movano has not generated any revenue to date.

Movano was founded in 2018 and plans to list on the Nasdaq under the symbol MOVE. National Securities is the sole bookrunner on the deal.

The article Glucose monitoring device developer Movano sets terms for $36 million IPO originally appeared on IPO investment manager Renaissance Capital's web site

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.